Renovis Announces Expiration of Hart-Scott-Rodino (HSR) 30-Day Waiting Period; Merger With Evotec on Track to Close in Early May, 2008

...ment of drugs for major medical needs in the areas of neurological and inflammatory diseases. The Company's proprietary research programs focus on the purinergic receptors, P2X3 and P2X7, for the potential treatment of pain and inflammatory diseases. In addition, Renovis has a worldwide collaboration and licens...

Renovis Announces Management Changes

... our portfolio of drug candidates for pain targeting members of the TRP and purinergic families of ligand-gated ion channels. Our team's work led to our collabora...ammatory diseases. The Company's proprietary research programs focus on the purinergic receptors, P2X3 and P2X7, for the potential treatment of pain and inflammat...

Purinergic in Biological Technology

Quantification of the Purinergic Receptor P2X3 using ICAT and Orthogonal 2D LC-MS/MS with an Ion Trap Mass Spectrometer

David Barnidge , Leo E. Bonilla , Gargi Choudhary Neuromics, Inc., Minneapolis, MN Thermo Finnigan, San Jose, CA ICAT Analysis The data prese...

Renovis Stockholders Approve Acquisition by Evotec

...ment of drugs for major medical needs in the areas of neurological and inflammatory diseases. The Company's proprietary research programs focus on the purinergic receptors, P2X3 and P2X7, for the potential treatment of pain and inflammatory diseases. In addition, Renovis has worldwide collaboration and license ...

Proxy Governance and Egan-Jones Recommend Renovis Shareholders Vote For Merger With Evotec

...ment of drugs for major medical needs in the areas of neurological and inflammatory diseases. The Company's proprietary research programs focus on the purinergic receptors, P2X3 and P2X7, for the potential treatment of pain and inflammatory diseases. In addition, Renovis has a worldwide collaboration and licens...

Glass Lewis & Co. Recommends Renovis Shareholders Vote For Merger With Evotec

...ment of drugs for major medical needs in the areas of neurological and inflammatory diseases. The Company's proprietary research programs focus on the purinergic receptors, P2X3 and P2X7, for the potential treatment of pain and inflammatory diseases. In addition, Renovis has a worldwide collaboration and licens...

Renovis Reports Fourth Quarter and Full Year 2007 Financial Results

...ment of drugs for major medical needs in the areas of neurological and inflammatory diseases. The Company's proprietary research programs focus on the purinergic receptors, P2X3 and P2X7, for the potential treatment of pain and inflammatory diseases. In addition, Renovis has a worldwide collaboration and licens...

Renovis Reports Third Quarter 2007 Financial Results

...ment of drugs for major medical needs in the areas of neurological and inflammatory diseases. The Company's proprietary research programs focus on the purinergic receptors, P2X3 and P2X7, for the potential treatment of pain and inflammatory diseases. In addition, Renovis has a worldwide collaboration and licens...

Renovis to Present at CIBC World Markets Healthcare Conference

...ment of drugs for major medical needs in the areas of neurological and inflammatory diseases. The Company's proprietary research programs focus on the purinergic receptors, P2X3 and P2X7, for the potential treatment of pain and inflammatory diseases. In addition, Renovis has worldwide collaboration and license ...

Monitoring Receptor-Mediated Changes in [Ca2+]i Using Single-Wavelength and Dual-Wavelength Indicators on the FlexStation Workstation

...s Health Science Center, Houston, Texas. ( http://www.tumor-gene.org/GPCR/gpcr.html ) 4. Strassheim, D. and Williams, C.L. (2000). P2Y 2 purinergic and M 3 Muscarinic Acetylcholine Receptors Activate Different Phospholipase C- Isoforms That Are Uniquely Susceptible to Protein Kinase C-dependent P...

Gq-coupled Receptor Assays Using FLEXstation

...ier, and J. M. Boeynaems. 1997. Cloning of a human purinergic P2Y receptor coupled to phospholipase C and adenyl... D. J. Adams, and B. J. Morris. 2000. Capacity for purinergic control of renin promoter via P2Y(11) receptor and.... 1998. ATP activates cAMP production via multiple purinergic receptors in MDCK-D1 epithelial cells. Blockade of...

Ca++-Induced G Protein Coupled Receptor (GPCR) Activation Monitored via Aequorin Luminescence in the LMax Microplate Luminometer (MaxLine Application Note #42)

...e curves for the activation of a Gqprotein-coupled purinergic receptor expressed endogenously in CHO cells. Thus... triphosphate (UTP) to activate the endogenous P2Y purinergic receptor. This receptor is known to be coupled to ...M coelenterazine(h), then exposed to UTP (a potent purinergic agonist), they responded with a rapid flash of lig...

Purinergic in Biological Products

Rabbit Anti-Human G-protein coupled purinergic receptor P2Y8 Polyclonal Antibody, Unconjugated from GenWay Biotech, Inc.

Description: G-protein coupled purinergic receptor P2Y8...
Company:GenWay Biotech, Inc.

Rabbit Anti-Human Purinergic Receptor P2Y12 Polyclonal Antibody, Unconjugated from IMGENEX

Description: Peptide-affinity Purified Polyclonal Antibody to Purinergic Receptor P2Y12...
Company:IMGENEX

Purinergic in Biological Dictionary

Adenosine

...ological actions and health effects. ... ADENOSINE , CAFFEINE AND ISCHEMIA/HYPOXIA. HEART DISEASE, CANCER AND CAFFEINE ... Adenosine can bind to purinergic receptors in different cell types where it can ... There is also evidence that adenosine inhibits calcium entry into the cell ... Learn about...